1. Huang P, Galloway CA, Yoon Y. Control of mitochondrial morphology through differential interactions of mitochondrial fusion and fission proteins. PLoS One. 2011. 6:e20655.
Article
2. Liesa M, Palacín M, Zorzano A. Mitochondrial dynamics in mammalian health and disease. Physiol Rev. 2009. 89:799–845.
Article
3. Chen KH, Guo X, Ma D, Guo Y, Li Q, Yang D, et al. Dysregulation of HSG triggers vascular proliferative disorders. Nat Cell Biol. 2004. 6:872–883.
Article
4. Liu YP, Wen SJ, Liu Y, Zhao LM, Guo YH, Chen XJ, et al. [Hyperplasia suppressor gene expression in vascular smooth muscle cells derived from normotensive and hypertensive patients underwent bypass surgery]. Zhonghua Xin Xue Guan Bing Za Zhi. 2007. 35:914–918.
5. de Brito OM, Scorrano L. Mitofusin-2 regulates mitochondrial and endoplasmic reticulum morphology and tethering: the role of Ras. Mitochondrion. 2009. 9:222–226.
Article
6. Pashkow FJ. Oxidative Stress and Inflammation in Heart Disease: Do Antioxidants Have a Role in Treatment and/or Prevention? Int J Inflam. 2011. 2011:514623.
Article
7. Guo X, Chen KH, Guo Y, Liao H, Tang J, Xiao RP. Mitofusin 2 triggers vascular smooth muscle cell apoptosis via mitochondrial death pathway. Circ Res. 2007. 101:1113–1122.
Article
8. Yu H, Guo Y, Mi L, Wang X, Li L, Gao W. Mitofusin 2 inhibits angiotensin II-induced myocardial hypertrophy. J Cardiovasc Pharmacol Ther. 2011. 16:205–211.
Article
9. Wang Z, Liu Y, Liu J, Liu K, Wen J, Wen S, et al. HSG/Mfn2 gene polymorphism and essential hypertension: a case-control association study in Chinese. J Atheroscler Thromb. 2011. 18:24–31.
Article
10. Farré D, Roset R, Huerta M, Adsuara JE, Roselló L, Albà MM, et al. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res. 2003. 31:3651–3653.
Article
11. Lenfant C, Chobanian AV, Jones DW, Roccella EJ. Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Hypertension. 2003. 41:1178–1179.
Article
12. Wang Z, Peng X, Tao Y, Liu Y, Liu J, Chen X, et al. Is prehypertension really different from normotension and hypertension? A case-control pilot proteomic study in Chinese. Clin Exp Hypertens. 2009. 31:316–329.
Article
13. Wang Z, Liu Y, Liu J, Liu K, Lou Y, Wen J, et al. E-selectin gene polymorphisms are associated with essential hypertension: a case-control pilot study in a Chinese population. BMC Med Genet. 2010. 11:127.
Article
14. Sato-Otsubo A, Sanada M, Ogawa S. Single-nucleotide polymorphism array karyotyping in clinical practice: where, when, and how? Semin Oncol. 2012. 39:13–25.
Article
15. O'Neill SM, Yun JK, Fox TE, Kester M. Transcriptional regulation of the human neutral ceramidase gene. Arch Biochem Biophys. 2011. 511:21–30.
16. Zhang K, Rao F, Wang L, Rana BK, Ghosh S, Mahata M, et al. Common functional genetic variants in catecholamine storage vesicle protein promoter motifs interact to trigger systemic hypertension. J Am Coll Cardiol. 2010. 55:1463–1475.
Article
17. Katkoori VR, Jia X, Chatla C, Kumar S, Ponnazhagan S, Callens T, et al. Clinical significance of a novel single nucleotide polymorphism in the 5' untranslated region of the Rabphillin-3A-Like gene in colorectal adenocarcinoma. Front Biosci. 2008. 13:1050–1061.
Article
18. Li N, Wang H, Yang J, Zhou L, Hong J, Guo Y, et al. Genetic variation of NEDD4L is associated with essential hypertension in female Kazakh general population: a case-control study. BMC Med Genet. 2009. 10:130.
Article
19. Pimenta E, Oparil S. Prehypertension: epidemiology, consequences and treatment. Nat Rev Nephrol. 2010. 6:21–30.
Article
20. Selassie A, Wagner CS, Laken ML, Ferguson ML, Ferdinand KC, Egan BM. Progression is accelerated from prehypertension to hypertension in blacks. Hypertension. 2011. 58:579–587.
Article